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Abstract 
Objective. To assess the stature of children with type 1 diabetes mellitus at diagnosis. 
Methods. We collected data from 451 records of children who were examined in a pediatric diabetes 
clinic and used data from the Third National Health and Nutrition Examination Survey for 10 522 
children as control group. Analytical techniques included linear and logistic regression modeling. A 
semiquantitative meta-analysis evaluated 38 earlier publications that contain information on height at 
the onset of diabetes. 
Results. Children <1 year of age were shorter than their peers by 1 standard deviation, whereas those 
from 3 years to near puberty were taller by approximately 0.3 standard deviation. Adjusting for 
parental height caused this difference to disappear for the older children but not for the infants. The 
meta-analysis results paralleled these observations. 
Conclusions. Taller children generally seem to experience increased risk for development of diabetes 
mellitus type 1, except perhaps during infancy or early adolescence. This observation may have 
implications regarding pathogenesis of this disorder. 
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Several reports examined the heights of children at initial diagnosis of type 1 diabetes mellitus (DM-1) 
previously but failed to achieve consensus regarding growth patterns.1–9 Some suggested that, 
depending on age or gender, heights of children with diabetes exceeded those of their peers; others 
failed to demonstrate this phenomenon, and a few reported shorter stature. Confirmation of a height 
discrepancy might provide some insight into the pathogenesis of DM-1. Increased height could support 
either the hypothesis that excess insulin secretion during the prodromal phase induces increased 
growth or that taller children experience increased risk of the development of DM-1. Increased growth 
tends to be associated with altered cellular regulatory functions. 
Before the onset of symptoms, children with DM-1 exhibit islet cell hyperplasia accompanied by a 
period of increased insulin secretion.10 Similarly, the nondiabetic, identical twin siblings of patients 
with DM-1 demonstrate increased serum concentrations of basal insulin and C-peptide.11,12 If insulin 
promotes linear growth, then children who are passing through this prodromal phase of anabolism and 
hyperinsulinemia may experience enhanced growth velocity, leading to increased height at diagnosis. 
We explored this relationship in 2 ways. An analysis was conducted of a large cohort of children 
examined by 1 of us, as well as a semiquantitative meta-analysis of all identifiable, previously published 
reports of the growth status of children at the time of diagnosis. The cohort study differs from earlier 
reports in several ways. It was larger and contained a higher proportion of infants and toddlers, 
increasing its power to detect height differences. For comparison, we used a large, scientifically 
selected, contemporaneous population, which increased validity and power. Finally, the availability of 
parental height reports allowed us to control for this important determinant of childhood stature in 
our analyses. This enhanced our ability to assess the direction of causality in the relationship between 
height and disease state and perhaps determine whether diabetes induced taller stature or taller 
stature led to an increased risk of diabetes. 
METHODS 
We reviewed the records of 451 children who ranged in age from 1 month to 18 years and whose DM-
1 was diagnosed between 1988 and 1998 in the Pediatric Diabetes Clinic at the Medical College of 
Wisconsin. The recorded time of initiation of insulin therapy represented the date of onset. We 
excluded records that were missing growth measurements within 3 months of diagnosis, those with 
type 2 diabetes, and those that had previously diagnosed medical conditions or environmental 
circumstances that potentially affected growth (eg, celiac or thyroid disease, chromosomal 
aberrations, methylphenidate therapy, history of any chronic disease, foster care). After these 
exclusions, 446 records—representing 217 girls and 229 boys—remained for analysis. The endocrine 
clinic nurse, specially trained in the technique, measured all children using the same stadiometer 
(Holtain Limited, Crymych, Wales, United Kingdom). Their parents provided heights by recall—a 
method of previously demonstrated validity.13,14 
Children who participated in the Third National Health and Nutrition Examination Survey (NHANES III) 
composed the control group.15 From 1988 through 1994, NHANES III examined 13 944 children 
between 2 months and 18 years of age, including detailed anthropometric measurements, parental 
heights, and family history. They oversampled the 2-month to 6-year age groups. We excluded children 
with medical conditions as noted above, as well as those whose parents reported any of these 
conditions before 18 years, or diabetes at any time. After also excluding those who were missing 
height or parental height measurements, 10 522 remained as a comparison population. We assigned z 
scores in standard deviations (SD) to all children based on this group. 
Statistical Analysis and Data Sources 
We compared the mean z score of the entire cohort of children with diabetes with that of the control 
group using the Student t test. All other analyses used regression techniques. Despite the relatively 
large cohort size, statistical power considerations mandated some data grouping to perform 
satisfactory age analysis. Therefore, with the exception of the 1-year-old and 2-year-old data points, 
each analysis used a variation of the moving average technique.16 For example, the calculations for the 
data point representing age 4 used ages 3, 4, and 5 data. This approach carried forward through the 
age 17 data point but leads obviously to the omission of ages 3 and 18 data points. The age 1 data 
point represents all children younger than 365 days, whereas the age 2 data point represents all 
children between 1 and 2 years. We chose to assess the 1- and 2-year age groups separately because 
preliminary data analysis suggested an inflection in the height–diabetes association in this range. 
The relationships among height (z score), age, gender, diabetic status, maternal height, and paternal 
height were modeled using linear and logistic regression with the “regress” and “logistic” commands, 
respectively, in the statistical software package Stata, (version 5; Stata Corporation, College Station, 
TX). The linear regression model used z score as the dependent variable with age, sex, diabetic status, 
maternal height, and paternal height as covariates, whereas in the logistic model, diabetic status and z 
score changed places. We also examined the relationship by age between height and diabetic status 
for each sex separately using linear regression. The Stata t test command compared the mean z scores 
for the 2 groups. 
Meta-analysis 
Using standard Medline search techniques, we identified relevant publications, then traced every 
seemingly appropriate reference in these reports.17 This approach led to the identification of 46 earlier 
studies for potential analysis. Several had little useful information, or the initial reference misquoted or 
misinterpreted the results; after review and exclusions, 36 remained. Few articles included the 
information needed for a quantitative meta-analysis, so we could not combine the results for all 
children. We did, however, examine the design of each, determining in particular its power to identify 
a difference between the study population and either a control group or standard population height 
values using the statistical software package, nQuery Advisor (Release 3.0; Statistical Solution Ltd, 
Cork, Ireland). In the former instance, we estimated power for a 2-sample Student t test, in the latter a 
1-sample test. To achieve a power of 90% with a type 1 error rate of 5% and an intergroup difference 
of 0.25 SD requires 338 or 171, respectively, in each group. We chose the 0.25-SD interval based on our 
own data and information from earlier reports. 
RESULTS 
The entire diabetic group was taller than its NHANES III counterpart by approximately 0.2 SD (P < 
.0001); among the children who were older than 1 year, the difference was 0.22 SD (P < .00005). 
Infants with diabetes (<1 year) were shorter than their peers by approximately 1.0 SD, with the effect 
limited to boys—with a z score of −1.6 SD (P < .002; Fig 1, Table 1). During the second year, this 
difference disappeared. Subsequently, from time periods 4 (3–5 years) through 7 (6–8 years), children 
with diabetes exceeded their peers, with a maximum differential of 0.3 SD for period 4. During the pre- 
and early adolescent era, periods 8 (7–9 years) through 10 (9–11 years), heights were similar, but from 
period 11 through 14, the children with diabetes were again taller than their peers with a peak 
differential of 0.34 SD at period 12 (11–13 years). After 14 years, the differences in height again 
became insignificant. Girls with diabetes were taller until completion of the adolescent growth spurt, 
whereas boys exhibited a triphasic curve, initially shorter, then taller until age 8, then equal for several 
years, then taller again. 
 
Fig 1.  Linear and logistic regression results of modeling the relationship DM-1 and height at the onset 
by age. The linear regression coefficients represent the (unadjusted) difference in height between 
children with diabetes and NHANES III children; the odds ratio represents the risk of developing DM-1 
associated with each SD increase in height. 
TABLE 1. Moving Average Linear Regression Coefficients by Age 
 
Age All P Female P Male P 
1 -1.0 .009 0.15 .82 -1.63 .002 
2 -0.05 .8 0.26 .42 -0.2 .4 
3 NA NA NA NA NA NA 
“4”* 0.3 .004 0.34 .023 0.27 .075 
“5” 0.27 .009 0.44 .006 0.15 .26 
“6” 0.26 .01 0.3 .056 0.23 .08 
“7” 0.22 .05 0.33 .061 0.15 .31 
“8” 0.12 .32 0.16 .33 0.08 .65 
“9” 0.065 .57 0.21 .15 -0.13 .46 
“10” 0.12 .25 0.18 .19 0.04 .79 
“11” 0.27 .008 0.29 .029 0.25 .123 
“12” 0.35 .001 0.19 .22 0.5 .001 
“13” 0.34 .004 0.27 .095 0.41 .017 
“14” 0.25 .05 0.16 .39 0.33 .063 
“15” 0.28 .07 0.3 .17 0.25 .24 
“16” 0.1 .6 -0.01 .98 0.17 .5 
“17” 0.14 .61 -0.07 .91 0.2 .54 
NA indicates not applicable. 
For all children adjusted for sex, and by sex. The coefficients represent the difference in height (in z score units) 
between children with diabetes and the control group. 
* The unquoted numbers are actual ages; quoted numbers are midpoints of 3-year eras. 
 
As expected, logistic regression models demonstrated a parallel but converse relationship between the 
risk for diabetes and height (Fig 1). During infancy, shorter children experienced a greater risk, but 
subsequently the burden fell on taller children. Adjustment for parental stature eliminated any height 
differential in the linear regression model and risk differential in the logistic regression model, except 
during infancy, when the adjusted regression coefficients and odds ratios remained unchanged. 
Meta-analysis 
The 38 earlier reports and the present one fell naturally into 4 categories: 1) a sufficient number of 
participants to meet the power requirements determined above, accompanied by formal statistical 
analysis; 2) an insufficient number of participants, with some statistical analysis; 3) an insufficient 
number of participants, with a qualitative judgment of differences; and 4) identical twin studies (Table 
2).1–9,18–46 Three investigations and the present one fit category 1; each found the children with 
diabetes generally taller, but a subset analysis in 1 found children <5 years shorter.9 In group 2, 11 
studies found children with diabetes taller and 4 not significantly different. Ten of the 17 studies in 
group 3 found children with diabetes taller, 1 shorter, 4 the same height, and 2 either taller or the 
same depending on population standards. The study reporting shorter heights suggested a 
socioeconomic cause for the difference. The twin studies all came from the same institution, and at 
least some of the records seem to be identical, but the authors do not clarify this issue or reference 
their own earlier reports. The twins represented in the analysis compose fewer than half of the total 
followed—leading to the possibility of selection bias. Although the second twin to develop diabetes 
among the concordant pairs seemed to experience growth deceleration in the interval before the 
onset of clinical disease, the small sample size (N = 16) precludes statistically meaningful conclusions. 
Likewise, the absence of a comparison with population standards prevents making generalizable 
inferences. 
TABLE 2.  Publications Used in Meta-analysis 
 
First Author N Power (%) Results 
Group 1    
Blom et al18 337  Taller 
Brown et al9 184  0–5 shorter; 5–10 taller; 10+ same 
Holl et al19 436  Taller 
Group 2    
Pond20 101  Boys/girls taller (P < .05/.001) 
Evans et al21 104 71 No difference 
Drayer2 62  Boys 4–9/4–14 taller; girls 4–9 shorter 
Edelsten et al3 44  Boys taller 
Court et al22 121 77 No difference 
Hjelt et al23 91  Taller (P < .0125) 
Jefferson et al24 92  Taller (5–10) 
Songer et al4 200  0–4 shorter; 5–9 taller; 10–13 no difference; 14+ shorter 
Emmerson and Savage5 66 51 No difference 
Price and Burden6 115  Taller (up to 3 y before diagnosis) 
Wise et al8 122  Taller 
Salerno et al25 62  Taller 
Bognetti et al26 152  Taller 
Scheffer-Marinus et al27 30  Taller (P < .015) 
Choudhury and Stutchfield28 61 48 No difference 
Group 3    
Joslin et al29 302  Taller 
Priesel and Wagner30 38  Taller 
Ladd31 34  Taller 
White1 100  Taller 
Boyd and Nelson32 20  Taller 
Spencer33 45  Taller 
Rabinowitch and Bazin34 71  Taller 
Fischer et al35 44  Taller 
Jackson and Kelly36 120 77 No difference 
Beal37 201 66 No difference 
Hamne38 155  Shorter 
Craig39 80 59 No difference 
Jivani and Rayner40 116 76 No difference 
Draminsky Petersen et al41 99 69 No difference 
Salardi et al42 79 59 No difference 
Thon et al7 89  Taller 
DuCaju et al43 46  Taller 
Group 4    
Tattersall and Pyke44 35   
Hoskins et al45 16   
David et al46 12   
Power analysis figures included for those studies reporting no difference in height between diabetic children and 
control group or standard population. 
DISCUSSION 
The results of our cohort analysis confirm and expand earlier suggestions that, at the time of diagnosis, 
the heights of children with DM-1 generally exceed those of their peers.19–21,27,33 The relatively small 
difference, 0.2 to 0.3 SD, may explain why some previous investigations failed to identify a discrepancy. 
These studies all had inadequate power to detect a difference of this size and provide virtually no 
evidence for the claim that the heights of children with diabetes at onset resemble those of their 
peers. The large number of children in each of our own groups led to high statistical support for the 
hypothesis that children with diabetes at diagnosis are taller than other children. 
Efforts to control potential sources of bias during this investigation included measuring all children on 
the same stadiometer and maintaining a short interval between diagnosis and height determination—
95% within 3 weeks. We considered 3 months as an acceptable upper limit because this time 
increment should have had little impact on any height differential present at the time of diagnosis. 
Data collection for NHANES III and our study was primarily contemporaneous. Four infants with 
diabetes were born after the completion of NHANES III, and some NHANES III adolescents came from 
slightly older birth cohorts than our oldest children. Bias attributable to secular trends should have 
been most evident in these cohorts, 15 to 18 years, because those children had the largest potential 
discrepancy in birth years. In fact, the oldest children failed to exhibit differences in height and the 
infants with diabetes were shorter, making the issue of this potential bias effectively moot. 
Among children between the ages of 3 and 8, as well as those between 10 and 15 years, measured 
heights exceeded those of the control group by approximately 0.3 SD. Analyses of the intervening ages, 
8 through 10 years, perhaps failed to demonstrate discrepant heights because growth variability 
introduced by the timing of puberty overwhelmed any underlying relationship between diabetes and 
height. 
In aggregate, earlier publications present a consistent picture of the stature of children with DM-1 at 
diagnosis. Their heights exceed those of their peers, except for the first few years, when some 
exhibited decreased stature, and the adolescent years, when no trends emerged. These results may 
seem somewhat surprising in view of the ongoing trend for publications to claim that earlier literature 
presents a confused picture—allowing for the inference of shorter, taller, or similar heights.5,9,18,26,43 
We believe that our meta-analysis should definitively end such confusion, but with 2 caveats. First, 
some of the height differences in earlier reports might conceivably be attributable to secular trends. 
Publication bias—the alleged tendency for journals to publish only positive results—also must be 
considered. Clearly, the reports that we analyzed primarily found positive results, but for most—all but 
4 papers—assessing the height at onset was a subsidiary finding, greatly reducing the likelihood of 
publication bias. We believe that neither potential source of bias substantially influences the 
preponderance of evidence from earlier reports. At diagnosis, children with diabetes from 5 to 10 
years exceed their peers in height. Younger children—or perhaps only boys—may be shorter. Small 
average study size prevented adequate assessment of the relationship of sex to stature. 
The observed differences between groups allow for reasoning about causality in 2 directions: diabetes 
mediates variations in growth, or growth variability influences risk for diabetes. Logically, statistical 
analyses support either interpretation: linear regression models view the impact of diabetes on height, 
whereas logistic models examine the impact of height on risk. Increased stature may represent an 
epiphenomenon of the islet-cell hyperplasia and hyperinsulinemia, which characterize the preclinical 
stages of diabetes.10–12 The impact of parental height adjustment, however, biases us toward the 
hypothesis that increased stature enhances the risk of childhood diabetes, at least among the children 
older than 3 years. Children with diabetes were taller than their peers, but only by the amount 
attributable to their parents’ increased stature. Unless we postulate that these children were initially 
shorter than expected, then grew taller as a consequence of presymptomatic diabetes, it is difficult to 
believe in the diabetes–growth causality direction. We therefore suggest that increased parental 
height leads to increased childhood height, which increases risk for diabetes. Accelerated intrauterine 
or childhood somatic growth, juxtaposed with a strong immunogenetic backdrop, may promote islet-
cell destruction.47,48 Curiously, growth hormone therapy may increase the risk of DM-2 but not DM-1.49 
The short stature among our infants with diabetes suggests the possibility that small infants may 
experience increased risk for early-onset diabetes. Although recent evidence supports increased risk 
among larger or more rapidly growing infants for childhood-onset DM-1, these observations may 
represent some degree of differential pathogenesis between diabetes developing in infancy and 
diabetes developing later in childhood.47,48,50,51 Infants who are small at birth or during the first year of 
life may experience intrauterine or early infantile stress, predisposing them to a variety of diseases in 
childhood and adulthood, including diabetes (type 2).52–54 Because parental height adjustment failed to 
modify the regression coefficient for height differential for infants, a perinatal environmental event 
seems most likely. Intrauterine growth retardation perhaps critically affects islet-cell development in 
some children. Alternatively, DM-1 may profoundly inhibit growth among younger boys before 
diagnosis—it would, however, require a reduction in growth velocity of 50% for approximately 3 
months for the observed 1.6 SD decrement to develop. The meta-analysis provides additional support 
for these observations. Three reports found reduced heights in the 0 to 4 interval, 1 emphasizing 
boys.9,25,36 
CONCLUSION 
The heights of children with newly diagnosed diabetes beyond infancy exceed those of age-matched 
control subjects (except pre- and early adolescent ages 8–10), seeming to reflect taller parental 
stature. This observation, as well as the diminished growth in infancy, may shed light on underlying 
pathogenic mechanisms and lead to new research directions regarding the cause of DM-1. 
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